- Fenofibric acid
-
- $99.00/ kg
-
2024-10-12
- CAS:42017-89-0
- Min. Order: 0.00100000kg
- Purity: 99%
- Supply Ability: 5000
- Fenofibric Acid
-
- $180.00 / 1kg
-
2024-10-12
- CAS:42017-89-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20ton
|
| Fenofibric acid Basic information |
| Fenofibric acid Chemical Properties |
Melting point | 177-179°C | Boiling point | 486.5±35.0 °C(Predicted) | density | 1.286±0.06 g/cm3(Predicted) | storage temp. | 2-8°C | solubility | Chloroform (Slightly), Methanol (Slightly) | pka | 3.09±0.10(Predicted) | form | powder | color | White to Off-White | BRN | 2058973 | CAS DataBase Reference | 42017-89-0(CAS DataBase Reference) |
Hazard Codes | Xn,N | Risk Statements | 36/37/38-50/53-22 | Safety Statements | 26-36/37/39-61-60-24/25 | RIDADR | UN 3077 9 / PGIII | WGK Germany | 3 | RTECS | UA2453000 | HazardClass | 9 | PackingGroup | III | HS Code | 29189900 | Toxicity | LD50 oral in rat: 1242mg/kg |
| Fenofibric acid Usage And Synthesis |
Chemical Properties | White to Off-White Solid | Uses | Fenofibric acid, the active metabolite of fenofibrate. Increases Apolipoprotein A-Iediated High-Density Lipoprotein Biogenesis by enhancing transcription of ATP-Binding cassette transporter A1 gene in a liver X receptorependent manner | Uses | Fenofibric acid, the active metabolite of fenofibrate. Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by enhancing transcription of ATP-Binding cassette transporter A1 gene in a liver X receptor–dependent manner. | Uses | DPP4 inhibitor, antidiabetic | Definition | ChEBI: A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate. |
| Fenofibric acid Preparation Products And Raw materials |
|